Werewolf and Ambros Merge in All-Stock Deal to Fund Phase III Neridronate Trial

Companies: Werewolf Therapeutics · Ambros Therapeutics · Event Type: All-Stock Merger · Combined Entity: Ambros Therapeutics (Nasdaq: AMBX) · Lead Asset: Neridronate · Date: August 21, 2026 Summary Werewolf Therapeutics and privately-held Ambros Therapeutics are combining in an all-stock, reverse-merger-style transaction, with Ambros valued pre-money…